REVIEW OF: Durgam S et al, J Clin Psychopharmacol 2025;45(2):67–75

STUDY TYPE: Randomized, double-blind, placebo-controlled trial

Mixed features—when depressive episodes include at least three manic symptoms—are tough to treat and linked to worse outcomes. Lurasidone has the strongest RCT evidence in this population, while cariprazine, olanzapine, and ziprasidone are supported but mostly through post-hoc or limited data. Optimal treatment is still unclear.

This 6-week industry-funded trial tested lumateperone (Caplyta) 42 mg, a serotonin/dopamine/­glutamate-modulating antipsychotic, vs placebo in 383 adults (18–75) with either major depressive disorder (MDD) or bipolar depression, all with mixed features as defined by DSM-5.

Lumateperone significantly improved depressive symptoms (MADRS scores) compared with placebo across all groups: combined MDD/bipolar (-5.7 points; 95% confidence interval [CI] [-7.60, -3.84]; effect size [ES] -0.64; p < 0.0001), MDD alone (-5.9; 95% CI [-8.61, -3.29]; ES -0.67; p < 0.0001), and bipolar alone (-5.7; 95% CI [-8.29, -3.05]; ES -0.64; p < 0.0001). Benefits were evident by day 15 and included higher remission rates (38.5% vs 19.9% with placebo). Lumateperone also improved overall severity (CGI-S) and manic symptoms (YMRS).

Tolerability was favorable. The most common side effects were somnolence (12.5%), dizziness (12%), and nausea (9.9%). No mania or hypomania emerged, and weight, metabolic, and extrapyramidal symptoms (EPS) were minimal.

CARLAT TAKE
This is the first placebo-controlled trial of lumateperone in mixed depression. The results are promising, but independent replication would be helpful. Rapid improvements, robust remission rates, moderate effect sizes, and a relatively clean metabolic/EPS profile stand out. The target dose is the same as in bipolar depression: 42 mg once daily.